MOESM1 of Extraordinary clinical benefit to sequential treatment with targeted therapy and immunotherapy of a BRAF V600E and PD-L1 positive metastatic lung adenocarcinoma

Abstract

Additional file 1. Full report of comprehensive genomic profiling (CGP) based on FoundationOneÂŽ panel